{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"4.410","floor":"3.420"},"ipodate":{"start":"2019-04-25 00:00:00","end":"2019-04-30 00:00:00"},"minimumcapital":"2227.22","subscribed":"106.92","marketcap":"66.15億","H_marketcap":"--","pe":"64.38","codesrate":"100.00","link":"https://staticpdf.iqdii.com/stockdata/notice/Prospectus/01873/LTN20190425036_C.pdf","ipopricing":"4.410","resultdate":"2019-05-08 00:00:00","enddate":"2019-04-30 00:00:00","listeddate":"2019-05-09 00:00:00","issuenumber":"34500.00萬","issuenumberhK":"17250.00萬","issuenumberother":"17250.00萬","grayprice":"4.55","sponsors":"中國國際金融香港證券有限公司","raisemoney":"137250.00萬","use":"1、約30%或411.8百萬港元將用于擴大EFS模式，將更多前景可觀的中國及海外生物科技初創公司加入我們的孵化投資企業組合；\n2、約30%或411.8百萬港元將用于建立商業及研究制作能力及生物CMO及化學CMO的能力；\n3、約10%或137.3百萬港元將用于按擴充計劃購置實驗室設備及物料；\n4、約10%或137.3百萬港元將用于招聘、培訓及保留生物及化學藥物研發人員；\n5、約10%或137.3百萬港元將用于擴充CMO業務，可能包括收購新技術、業務或服務，及╱或與第三方建立戰略聯盟；\n6、約10%或137.3百萬港元將用作我們的一般公司及營運資金。","shares":500,"leadagent":"中國國際金融香港證券有限公司,摩根大通證券(亞太)有限公司,野村國際(香港)有限公司,中銀國際亞洲有限公司,華興證券(香港)有限公司,海通國際證券有限公司,大和資本市場香港有限公司,第一上海證券有限公司","bookrunners":"中國國際金融香港證券有限公司,摩根大通證券(亞太)有限公司,野村國際(香港)有限公司,中銀國際亞洲有限公司,華興證券(香港)有限公司,海通國際證券有限公司","coordinator":"中國國際金融香港證券有限公司,摩根大通證券(亞太)有限公司,野村國際(香港)有限公司","firstDayOpen":"4.51","IsEiio":0,"Interestdays":8,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"中國國際金融香港證券有限公司","code":"E01873","name":"維亞生物","fullname":"維亞生物科技控股集團"},"institutioninfo":{"principaloffice":"中國上海浦東新區張江高科技園區愛迪生路334號","registrars":"卓佳證券登記有限公司","registrarstel":"(852)2980 1333","chairman":"毛晨","secretary":"費曉玉,周慶齡","telephone":"(86021)6089 3288","substantialshareholders":"毛晨(29.31%),Zhang and Son(10.63%),Fenghe Harvest(10.32%),China Finance Strategie(8.26%),Wu and Sons(6.27%)","principalactivities":"公司營運一個領先的基于結構的新藥發現技術平臺，具有多項全球領先的技術以及具拓展性的業務模式，以分享客戶知識產權的增值潛力。","website":"http://www.vivabiotech.com"},"managerinfo":[{"managername":"毛晨","post":"主席、首席執行官兼執行董事","rankno":1},{"managername":"任德林","post":"總裁兼執行董事","rankno":2},{"managername":"吳鷹","post":"常務副總裁兼執行董事","rankno":3}],"investorinfo":[{"institutionname":"深圳市高特佳睿寶投資合伙企業(有限合伙)","shareholding":"32,011,000.0","percentage":9.28,"ReleaseDate":"2019-11-09 00:00:00","relatedparty":"深圳市高特佳投資集團有限公司","subsidiary":["Gaotejia Investment Management Co., Ltd","深圳市高特佳睿寶投資合伙企業(有限合伙)","瑞捷軟件科技(香港)有限公司"],"InverstorType":"公司"},{"institutionname":"中國醫藥投資有限公司","shareholding":"26,483,000.0","percentage":7.68,"ReleaseDate":"2019-11-09 00:00:00","relatedparty":"中國醫藥集團有限公司","subsidiary":["中國醫藥投資有限公司"],"InverstorType":"公司"},{"institutionname":"Gaotejia Investment Management Co., Ltd","shareholding":"21,340,500.0","percentage":6.19,"ReleaseDate":"2019-11-09 00:00:00","relatedparty":"深圳市高特佳投資集團有限公司","subsidiary":["Gaotejia Investment Management Co., Ltd","深圳市高特佳睿寶投資合伙企業(有限合伙)","瑞捷軟件科技(香港)有限公司"],"InverstorType":"公司"}],"TotalShareholdingPercentage":23.15},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":520}